Leerink Partnrs downgraded shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) from an outperform rating to a market perform rating in a research note released on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Fusion Pharmaceuticals’ Q1 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.40) EPS and FY2025 earnings at ($1.42) EPS. Other […]
B. Riley lowered shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) from a buy rating to a neutral rating in a research report sent to investors on Wednesday morning, Marketbeat reports. B. Riley currently has $23.00 price target on the stock, up from their previous price target of $13.00. Other equities research analysts have also […]
Fusion Pharmaceuticals (NASDAQ:FUSN) Downgraded to Hold at Brookline Capital Management theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Truist Financial Reaffirms Hold Rating for Fusion Pharmaceuticals (NASDAQ:FUSN) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Jefferies Financial Group reaffirmed their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research report report published on Tuesday, Marketbeat reports. They currently have a $21.00 price target on the stock, up from their prior price target of $10.00. FUSN has been the topic of several other reports. William Blair […]